pLenti-Cas9-P2A-Puro Citations (5)
Originally described in: Optimized base editors enable efficient editing in cells, organoids and mice.Zafra MP, Schatoff EM, Katti A, Foronda M, Breinig M, Schweitzer AY, Simon A, Han T, Goswami S, Montgomery E, Thibado J, Kastenhuber ER, Sanchez-Rivera FJ, Shi J, Vakoc CR, Lowe SW, Tschaharganeh DF, Dow LE Nat Biotechnol. 2018 Jul 3. pii: nbt.4194. doi: 10.1038/nbt.4194. PubMed Journal
Articles Citing pLenti-Cas9-P2A-Puro
| Articles |
|---|
CRISPR-Switch regulates sgRNA activity by Cre recombination for sequential editing of two loci.
Chylinski K, Hubmann M, Hanna RE, Yanchus C, Michlits G, Uijttewaal ECH, Doench J, Schramek D, Elling U.
Nat Commun. 2019 Nov 29;10(1):5454. doi: 10.1038/s41467-019-13403-y.
PubMed
Associated Plasmids |
| Targeting the Atf7ip-Setdb1 Complex Augments Antitumor Immunity by Boosting Tumor Immunogenicity. Hu H, Khodadadi-Jamayran A, Dolgalev I, Cho H, Badri S, Chiriboga LA, Zeck B, Lopez De Rodas Gregorio M, Dowling CM, Labbe K, Deng J, Chen T, Zhang H, Zappile P, Chen Z, Ueberheide B, Karatza A, Han H, Ranieri M, Tang S, Jour G, Osman I, Sucker A, Schadendorf D, Tsirigos A, Schalper KA, Velcheti V, Huang HY, Jin Y, Ji H, Poirier JT, Li F, Wong KK. Cancer Immunol Res. 2021 Nov;9(11):1298-1315. doi: 10.1158/2326-6066.CIR-21-0543. Epub 2021 Aug 30. PubMed |
| Gene expression predicts dormant metastatic breast cancer cell phenotype. Ren Q, Khoo WH, Corr AP, Phan TG, Croucher PI, Stewart SA. Breast Cancer Res. 2022 Jan 29;24(1):10. doi: 10.1186/s13058-022-01503-5. PubMed |
Base editing sensor libraries for high-throughput engineering and functional analysis of cancer-associated single nucleotide variants.
Sanchez-Rivera FJ, Diaz BJ, Kastenhuber ER, Schmidt H, Katti A, Kennedy M, Tem V, Ho YJ, Leibold J, Paffenholz SV, Barriga FM, Chu K, Goswami S, Wuest AN, Simon JM, Tsanov KM, Chakravarty D, Zhang H, Leslie CS, Lowe SW, Dow LE.
Nat Biotechnol. 2022 Feb 14. pii: 10.1038/s41587-021-01172-3. doi: 10.1038/s41587-021-01172-3.
PubMed
Associated Plasmids |
| Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines. Fedier A, Maggi N, Tozzi A, Disler M, Coelho R, Jacob F, Heinzelmann-Schwarz V. Int J Oncol. 2022 Jul;61(1). pii: 89. doi: 10.3892/ijo.2022.5379. Epub 2022 Jun 1. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.